Taken together, these experiments demonstrate that the in situ gel vaccine loaded with GM-CSF, Dox-iRGD, and CpG enhances tumor-specific CD8+ and CD4+ T-cell activity in tdLNs and the systemic circulation, and slows the growth of 4T1 tumors. This evidence concerns the gene CSF2 and neoplasm.